No title
The most malignant brain tumour, glioblastoma multiforme (GBM), has an utterly bad prognosis. In spite of all available therapy, the mean survival time is less than a year. In the unique BRIGTT project (Brain Immuno Gene Tumour Therapy), patients at the Dept of Neurosurgery. Lund University Hospital, are immunised with their own glioma cells, which have been transfected with the immunostimulatory
